New Zealand launches new medical cannabis information service

Jun 16, 2022 Leave a message

A New Zealand medical cannabis company has partnered with a healthcare consultancy to provide medical cannabis information programmes in person and online across the country.

Helius Therapeutics, New Zealand's largest licensed medicinal cannabis company, has just announced an exclusive partnership with DATAPHARM, which aims to provide leading prescription drug education programmes and resources.

All patients and the public can register, and doctors, nurses and pharmacists can register for free. "We know that improving prescribers' knowledge is key to ensuring that more patients have access to medicinal cannabis. Helius has an unwavering commitment to education, so we are excited to once again partner with the best in the industry, "said Carmen Doran, CEO of Helius Therapeutics.

DATAPHARM has worked closely with the medicinal Cannabis division for the past three years, with director Mark Morrison advising Helius since late 2020. "Our exclusive partnership with DATAPHARM now fully fills the information vacuum in the field of medicinal cannabis. This is an exciting development for the industry and the most important patients, and Helius is pleased to lead the way, "dolan said.

Registration is strongly encouraged on the new www.mcinfo.com, which is available to all patients and the public and is free for doctors, nurses and pharmacists.

New Zealand Medical Cannabis Conference - MedCan 2021

Meanwhile, MedCan 2021, a local medical marijuana conference, is open for registration. "Scholars, researchers, government officials, doctors, business people, investors, entrepreneurs and innovators, growers and patients cannot miss the MedCan Summit in October 2021. It marks what BioTechNZ says is a real starting line for a sunrise industry, as local producers are taking positive steps towards entering the market, "reads a press release associated with the summit.

Dr. Zahra Champion, Executive director of BioTechNZ and organizer of MedCan 2021, said that with more than $100 million invested in the local medicinal cannabis industry, "2021 is our year to shine."

The event will link medicine, industry, science and technology and will invite leading international and national thought leaders. Areas covered will include seed sales, clinical trials, prescribing, patient case studies, and the social, cultural and economic benefits of the product to New Zealand.

"Local companies have been working for three years and have invested a lot. It's an expensive entrepreneurial endeavour, but New Zealand companies are on the verge of entering the market, which is good news for patients both at home and abroad, "Champion said.